__

EQ Labs, Inc. (PINK: EQLB)

EQ Labs Inc Products

What is EQ?

EQ is instant energy in any beverage, consisting of a blend of essential vitamins, Gingko Biloba and caffeine keeps you going any time, day or night. EQ is all about energy and living the All-American Lifestyle.

EQ is a great addition to your favorite beverage and mixable to your taste. Drop an EQ into water or any drink (alcoholic or non-alcoholic).

Essentially, one can place a tablet or tube of this product in their pocket or purse and immediately have an energy drink available in the short amount of time that it takes for the tablet to dissolve. Try carrying around six cans or bottles of energy drinks and you will see why EQ Labs encourages consumers to “Think Outside the Can.”

Latest News

EQ Labs Begins National Television Advertising Campaign

EQ Labs (Pink: EQLB) announced last week that it began a national advertising campaign with a 5 minute spot on ABC affiliate KTNV (Channel 13) in Las Vegas. Chief Executive Officer, Maurice Owens, was featured on “The Morning Blend” show talking about the virtues of EQ Energy drink while also displaying the company’s complete product line.

KTNV is owned by New York Stock Exchange-traded Journal Communications, Inc. The Company owns television stations, radio stations and newspapers in Arizona, Wisconsin, California, Florida and other major markets throughout the country.

In the interview, Owens stresses the health factor of EQ, “No sugar, five calories.”

Owens continued, “The flavors are super. We have Mo Apple and Strawberry Dream. It takes about 30 seconds to get going.”

Chief Executive Officer Owens also stated that the market for EQ is very large and that he expects EQ Energy drink to be in 5,000 additional stores by year end as the company’s products are already in 45 states. Owens stated that the “Healthy Energy Drink” is being used by students, truck drivers and young adults because of its wide spread appeal.

Owens added toward the end of the interview, “We have three top distributors so we have access to about 150,000 stores.”

The entire interview could be viewed by clicking on the following link:

http://www.vegasmorningblend.com/videos/100655614.html

About EQ Labs, Inc.

EQ Labs is engaged in the development, marketing and sale of EQ (”The Smart Energy Drink”). EQ is an effervescent tablet that can be dissolved in any beverage to provide instant energy. Consisting of a blend of essential vitamins, Gingko Biloba, and less caffeine than a cup of coffee. EQ is currently sold at Best Buy, 7-Eleven, Walgreens and other leading retailers.

http://www.drinkeq.com/

__

Proteonomix, Inc. (PROT) Plans European Investor Road Show

-Michael Cohen, Chairman and CEO, to Visit Several European Cities to Discuss Company’s Growth Plan and Future Outlook With Investors

PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced last week that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (”XGen”), a Nevis Island limited liability company.

For additional details about the joint venture agreement, please refer to the August 17, 2010 press release.

“Proteonomix has made great strides recently,” stated Mr. Cohen, “and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships.”

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD).

http://www.proteonomix.com/

__

PWRM, Power 3 Medical Products Inc., PWRM.OB

PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro).

PWRM continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS (Lou Gehrig’s disease), Alzheimer’s, Parkinson’s diseases, breast cancer, and drug resistance.

The NuroPro Blood Test is PWRM’s diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease .

PWRM’s BC-SeraPro(TM) is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to PWRM’s patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis. Probability score is ranged from 0.0 to 1.0. Results of PWRM’s BC-SeraPro(TM) test should not be considered a stand alone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.

PWRM expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD), Parkinson’s disease (NuroPro-PD) and breast cancer in 2010, followed by filings with the FDA.

www.power3medical.com

__

UnitedHealth Group to Invest $10 Million to Help Improve Health Care Information Technology Systems at California’s Critical Access Hospitals

UnitedHealth Group (NYSE: UNH) has announced it will invest $10 million to help California’s Critical Access Hospitals improve their health information technology (IT) systems and adopt electronic health records.

California’s Critical Access Hospitals are health care facilities with a maximum of 25 beds and located in a rural area at least 35 miles from another hospital, or a rural hospital that is 15 miles from another hospital in mountainous terrain or areas with only secondary roads.

The funds will be made available from UnitedHealth Group’s California Health Care Investment Program, a 20-year, $200 million commitment to health care organizations that provide services to underserved, low-income and underinsured communities and populations throughout California.

UnitedHealth Group is also providing $200,000 in grants to the California State Rural Health Association (CSRHA) to assess IT needs at California’s 31 Critical Access Hospitals. Once the assessments are completed, UnitedHealth Group, with input from CSRHA, will select the Critical Access Hospitals that will receive a total of $10 million in capital from UnitedHealth Group for health IT projects.

The selected hospitals will pool together for a $10 million bond offering that will be purchased by UnitedHealth Group at rates that are highly competitive with those of conventional financing. Additionally, UnitedHealth Group’s Capital Access Small Issuance Program will pay the entire bond issuance costs of about $800,000.

UnitedHealth Group’s UnitedHealthcare business offers health benefits, including commercial and Medicare health plans, to more than 2.8 million Californians, and partners with about 50,000 physicians across the state.

UnitedHealth Group is a diversified health and well-being company dedicated to helping people live healthier lives and making health care work better. With headquarters in Minnetonka, Minn., UnitedHealth Group offers a broad spectrum of health benefit programs through UnitedHealthcare, Ovations and AmeriChoice, and health services through Ingenix, OptumHealth and Prescription Solutions. Through its family of businesses, UnitedHealth Group serves more than 75 million people worldwide.

www.unitedhealthgroup.com

__

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DoubleInStocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: http://doubleinstocks.com/disclaimer) Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings, Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received fifteen thousand dollars in cash from a third party (EEA, Inc ) for (7) days of advertising for EQ Labs, Inc. (EQLB.PK)Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

____________________

Sign Up for our FREE Daily Stock Newsletter

____________________

DoubleInStocks would like to invite you to www.crowntradingsystems.com so you can check out the super 16 multi monitor super computer he trades on daily. If you’re looking for a multi display computer to enhance your trading then you’ll want to visit www.crowntradingsystems.com

 

 

Tags:

Energy Drink |  EQ Energy Team |  EQ Labs Inc |  EQLB.PK |  essential vitamins |  NYSE:UNH |  OTC:PROT |  otc:pwrm |  PINK:EQLB |  PROT |  PROT.OB |  PWRM |  PWRM.OB |  UNH |  UnitedHealth Group